iTeos Therapeutics, Inc

Werewolf Therapeutics, Inc., based in Watertown, MA, is an innovative biotechnology company focused on developing transformative cancer therapies through advanced immunotherapy techniques. Their proprietary PREDATOR protein engineering technology allows for the creation of conditionally activated proinflammatory immune modulators, designed to enhance the body's immune response to cancer while minimizing off-target effects on healthy tissues. The company's novel INDUKINE molecules are administered in an inactive form and selectively activated within the tumor microenvironment, unleashing a potent immune response against cancer cells. Led by a team of experienced physician-scientists and industry veterans, Werewolf Therapeutics aims to redefine the cancer treatment landscape with potentially best-in-class therapies that improve the lives of patients living with cancer. Generated from the website

Compass Therapeutics, Inc., located in Brighton, MA, is focused on developing next-generation antibodies aimed at transformative cancer therapies that enhance patients' lives. By leveraging their understanding of the tumor microenvironment, the company designs product candidates that optimize critical components necessary for an effective antitumor response to cancer. With a robust portfolio of therapeutic candidates that bridge the innate and adaptive immune systems, Compass Therapeutics is advancing its pipeline with exceptional speed and diversity. The company is committed to identifying therapeutic leads that can significantly impact cancer treatment through innovative approaches. Generated from the website

X-COR Therapeutics is a Baltimore-based medical device company dedicated to creating the first commercially available extracorporeal CO2 removal device that utilizes ultra-low-blood flow technology. Their innovative solution aims to treat patients experiencing hypercarbic respiratory failure, offering a more accessible, affordable, and effective alternative to existing therapies. Founded by a team of experienced professionals with expertise in pulmonary medicine, engineering, and business development, X-COR's patent-pending system allows for the safe removal of excess CO2 from patients' blood using a hybrid approach. This technology enables broader adoption across healthcare settings, empowering more clinicians to provide critical care to individuals suffering from respiratory conditions. Generated from the website